Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics
Lisa A. Radkay, Simion I. Chiosea, Raja R. Seethala, Steven P. Hodak, Shane O. LeBeau, Linwah Yip, Kelly L. McCoy, Sally E. Carty, Karen E. Schoedel, Marina N. Nikiforova, Yuri E. Nikiforov and N. Paul Ohori
Article first published online: 12 AUG 2014 | DOI: 10.1002/cncy.21474
RAS mutations are found in approximately 20% to 45% of thyroid neoplasms and are associated with carcinoma in 74% to 87% of cases (most commonly follicular variant papillary thyroid carcinoma). In the current study, the authors report that subclassification of RAS mutations provides better insight into lesional characteristics. In particular, KRAS12/13-mutated thyroid nodules are associated with a lower carcinoma outcome (41.7%) and frequent oncocytic changes.